Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. - Ball BJ; Xiao W; Borthakur G; Nguyen LXT; Valerio M; Venkatachalam A; Marcucci G; Stein AS; Thai DL; Cook DN; Chan K; Persaud S; et al. (Journal of hematology & oncology, 2025)